Table 2.
Intraocular pressure across visits and time pointsa
| Drug | Baseline
|
Week 2
|
||||||
|---|---|---|---|---|---|---|---|---|
| 8 am | 10 am | 3 pm | 5 pm | 8 am | 10 am | 3 pm | 5 pm | |
| BBFC | ||||||||
| Number | 209 | 209 | 209 | 209 | 209 | 205 | 205 | 204 |
| Mean (SD), mmHg | 26.9 (2.6) | 25.3 (2.8) | 23.7 (3.0) | 23.2 (3.1) | 19.7 (3.4) | 16.4 (3.0) | 17.8 (3.0) | 15.9 (2.9) |
| LS, mean (SE), mmHg | NA | NA | NA | NA | 20.4 (0.3) | 17.1 (0.3) | 18.4 (0.3) | 16.6 (0.3) |
| Brinzolamide | ||||||||
| Number | 224 | 224 | 224 | 224 | 223 | 221 | 220 | 220 |
| Mean (SD), mmHg | 27.1 (2.6) | 25.4 (2.7) | 23.8 (3.2) | 23.6 (3.4) | 21.3 (3.7) | 19.9 (3.4) | 19.7 (3.6) | 19.1 (3.3) |
| LS, mean (SE), mmHg | NA | NA | NA | NA | 22.0 (0.3) | 20.5 (0.3) | 20.4 (0.3) | 19.7 (0.3) |
| Brimonidine | ||||||||
| Number | 216 | 216 | 216 | 216 | 216 | 212 | 212 | 212 |
| Mean (SD), mmHg | 27.0 (2.6) | 25.4 (2.8) | 24.0 (3.3) | 23.7 (3.3) | 21.6 (4.1) | 18.6 (3.6) | 19.8 (3.9) | 17.6 (3.2) |
| LS, mean (SE), mmHg | NA | NA | NA | NA | 22.4 (0.3) | 19.4 (0.3) | 20.6 (0.3) | 18.4 (0.3) |
| P-valueb | ||||||||
| BBFC vs brinzolamide | NA | NA | NA | NA | <0.001 | <0.001 | <0.001 | <0.001 |
| BBFC vs brimonidine | NA | NA | NA | NA | <0.001 | <0.001 | <0.001 | <0.001 |
|
| ||||||||
|
6 wk
|
3 mo
|
|||||||
| 8 am | 10 am | 3 pm | 5 pm | 8 am | 10 am | 3 pm | 5 pm | |
|
| ||||||||
| BBFC | ||||||||
| Number | 198 | 197 | 196 | 196 | 189 | 189 | 189 | 189 |
| Mean (SD), mmHg | 19.7 (3.9) | 16.8 (3.4) | 18.3 (3.6) | 16.4 (3.4) | 19.8 (4.2) | 16.5 (3.6) | 18.0 (3.7) | 16.3 (3.7) |
| LS, mean (SE), mmHg | 20.4 (0.3) | 17.5 (0.3) | 18.9 (0.3) | 17.0 (0.3) | 20.5 (0.3) | 17.2 (0.3) | 18.7 (0.3) | 17.0 (0.3) |
| Brinzolamide | ||||||||
| Number | 215 | 214 | 214 | 214 | 213 | 213 | 212 | 212 |
| Mean (SD), mmHg | 21.2 (4.3) | 19.5 (3.7) | 19.5 (3.3) | 19.0 (3.5) | 20.9 (4.2) | 19.7 (4.0) | 19.7 (3.7) | 19.3 (3.7) |
| LS, mean (SE), mmHg | 21.9 (0.3) | 20.2 (0.3) | 20.2 (0.3) | 19.7 (0.3) | 21.6 (0.3) | 20.4 (0.3) | 20.4 (0.3) | 20.0 (0.3) |
| Brimonidine | ||||||||
| Number | 203 | 201 | 200 | 199 | 192 | 192 | 192 | 190 |
| Mean (SD), mmHg | 21.8 (4.3) | 18.6 (3.4) | 20.2 (3.9) | 17.7 (3.2) | 22.5 (4.4) | 18.9 (3.7) | 20.5 (3.8) | 17.9 (3.3) |
| LS, mean (SE), mmHg | 22.6 (0.3) | 19.5 (0.3) | 21.1 (0.3) | 18.6 (0.3) | 23.3 (0.3) | 19.7 (0.3) | 21.3 (0.3) | 18.8 (0.3) |
| P-valueb | ||||||||
| BBFC vs brinzolamide | <0.001 | <0.001 | <0.001 | <0.001 | 0.002 | <0.001 | <0.001 | <0.001 |
| BBFC vs brimonidine | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Notes:
a
Intraocular pressure was analyzed using the intent-to-treat population.
b
Pairwise t-test on LS means. Reprinted with permission from Katz G, Dubiner H, Samples J, Vold S, Sall K. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%. JAMA Ophthalmol. 2013;131(6):724–730.53 Copyright © 2013 American Medical Association. All rights reserved.
Abbreviations: BBFC, brinzolamide 1%/brimonidine 0.2% fixed combination.